CC BY-NC-ND 4.0 · Joints 2017; 05(01): 002-006
DOI: 10.1055/s-0037-1601405
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Single Platelet-Rich Plasma Injection for Early Stage of Osteoarthritis of the Knee

Liborio Ingala Martini
1  IRCCS Policlinico San Donato, Milan, Italy
,
Alessio Giai Via
1  IRCCS Policlinico San Donato, Milan, Italy
,
Chiara Fossati
1  IRCCS Policlinico San Donato, Milan, Italy
,
Filippo Randelli
1  IRCCS Policlinico San Donato, Milan, Italy
,
Pietro Randelli
1  IRCCS Policlinico San Donato, Milan, Italy
,
Davide Cucchi
1  IRCCS Policlinico San Donato, Milan, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
05 June 2017 (online)

  

Abstract

Purpose The purpose of this study was to determine the safety efficacy and outcomes of platelet-rich plasma (PRP) intra-articular injections for early stages of knee osteoarthritis (OA).

Methods Twenty-five patients affected by grade I and II knee primary OA according to the Kellgren–Lawrence scale received a single intra-articular PRP injection. Patients were prospectively evaluated for 6 months. Visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Knee injury and Osteoarthritis Outcome Score (KOOS) scoring scales were used to evaluate clinical outcomes. Wilcoxon signed rank test was used to evaluate significance of improvement of WOMAC, KOOS, and VAS scores.

Results Twenty-one patients completed 6-months follow-up. The median WOMAC score improved from 29.1 points (range: 17.4–60.4; standard deviation [SD] = 13.0) at baseline to 42.41 (range: 24.3–71.2; SD = 12.5) at final follow-up. Improvements in median KOOS and VAS score have been also found, from 37.49 points and 64.2 mm before injection to 59.71 points and 42.8 mm, respectively. All these improvements were statistically significant (p < 0.05). No adverse reactions have been observed.

Conclusion Treating knee OA with PRP injection is safe. A single dose of PRP seems to be effective in managing pain and improving quality of life in patients with low-grade knee OA.

Level of Evidence Level IV, therapeutic case series.